The Cooper Companies, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +65

Stifel Backs Cooper Companies (COO) as CooperSurgical Sale Talks Progress

AI-generated analysis

πŸ“ˆ Stifel reiterated a Buy rating on Cooper Companies (COO) with a price target of $85 following progress in selling the surgical unit.

πŸ’° The company plans to use the majority of proceeds from the CooperSurgical sale to fund share repurchases.

βš–οΈ All legal issues plaguing the CooperSurgical business unit have been settled, clearing the path for a potential divestiture.

πŸ‘οΈ Post-sale transformation will leave Cooper focused exclusively on its contact lens business under the CooperVision unit.

πŸ“Š Analysts estimate the stock could reach $80 per share after the sale, indicating roughly 21% upside from current prices.

🀝 Multiple parties have expressed interest in buying the surgical business unit according to company disclosures.

πŸ›οΈ Cooper Companies operates two main divisions: CooperVision for contact lenses and CooperSurgical for women's health products.

Bullish Signals
  • Stifel maintains a Buy rating with a specific price target of $85, suggesting strong analyst confidence in the company's valuation.
  • The settlement of all legal issues regarding the surgical unit removes a significant overhang and facilitates the planned sale.
  • Management intends to use the majority of the sale proceeds for share repurchases, which typically supports or boosts the stock price.
  • Multiple parties are actively interested in purchasing the CooperSurgical business, indicating strong market demand for the asset.
  • Billionaire Barry Rosenstein identifies COO as one of the best stocks to buy, adding high-profile institutional endorsement.
  • The company is backed by 49 hedge funds, demonstrating broad institutional ownership and confidence in the investment thesis.
Full Analysis
Stifel Securities has reiterated a Buy rating on Cooper Companies (NASDAQ: COO) with a price target of $85, following the company's announcement that it is advancing discussions to sell its surgical business unit, CooperSurgical. The brokerage views the recent settlement of all legal issues plaguing the unit as a positive signal that management is moving the sale talks to the next level, with multiple interested parties identified. Upon completion of the divestiture, Stifel estimates Cooper's stock could be worth $80 per share, representing approximately 21% upside from current levels. The company plans to utilize the vast majority of proceeds from the sale to fund share repurchases. This strategic move would transform Cooper into a focused contact lens manufacturer under its CooperVision unit. Cooper Companies operates two primary divisions: CooperVision, which produces contact lenses for vision correction, and CooperSurgical, focused on women's health products including genetic testing and fertility solutions. While the article notes that some analysts believe AI stocks offer higher returns, it highlights specific bullish metrics for COO, including backing from 49 hedge funds and a recommendation from billionaire Barry Rosenstein.